Clinical Research Directory
Browse clinical research sites, groups, and studies.
Assessment of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of GenSci120 in Healthy Adult Participants in China.
Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
Summary
This study is designed to evaluate the safety, tolerability, PK and PD of multiple subcutaneous injections of GenSci120 in a randomized, double-blind, placebo-controlled, multiple-ascending-dose phase Ib trial involving healthy adult participants.
Official title: A Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of GenSci120 in Healthy Adult Participants in China
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2025-08-01
Completion Date
2026-09-20
Last Updated
2025-08-06
Healthy Volunteers
Yes
Conditions
Interventions
GenSci120
a total of 3 doses of the investigational medicinal product (IMP) SC every four weeks (Q4W) at the planned dose level
Placebo
a total of 3 doses of the investigational medicinal product (IMP) SC every four weeks (Q4W) at the planned dose level
Locations (1)
Huashan Hospital Affiliated to Fudan University
Shanghai, Shanghai Municipality, China